# Venetoclax (Venclexta)

Source: https://ourhealthnetwork.com/drugs/venetoclax
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Venetoclax?

Venetoclax (brand name: Venclexta) is a bcl-2 inhibitor. It is prescribed to treat leukemia, lymphoid. Across the United States, 3,000 doctors prescribe Venetoclax to approximately 4,000 Medicare patients.

## Brand names

Venclexta

## Indications

Venetoclax is prescribed for the treatment of leukemia and lymphoid.

## Conditions treated

- [Leukemia](https://ourhealthnetwork.com/conditions/leukemia)
- [Lymphoid](https://ourhealthnetwork.com/conditions/lymphoid)

## Mechanism of action

Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL and AML cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics.

## Drug classification

- Established Pharmacologic Class: BCL-2 Inhibitor [EPC]
- Mechanism of Action class: P-Glycoprotein Inhibitors [MoA]
- Route of administration: ORAL

## Common side effects

covid-19, diarrhea, headache, musculoskeletal pain, neutropenia

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)